Clinical Trial

A Study of Avoralstat In Participants With Diabetic Macular Edema

Terminated Phase 1
View on ClinicalTrials.gov →
Why the trial stopped
Strategic decision
Summary
The goal of this study is to assess the safety and therapeutic potential of a single dose of avoralstat in adult participants with DME.
Protocol Amendment History 5 changes
critical Trial terminated 2026-05-12
critical Reason stopped changed: — → Strategic decision 2026-05-12
notable Enrollment reduced: 9 -> 3 participants 2026-05-12
minor Completion moved earlier: 2026-09 -> 2026-04-17 2026-05-12
critical Trial status changed: Recruiting → Active, Not Recruiting 2026-04-08
Trial Details
NCT Number NCT07228559
Lead Sponsor BioCryst Pharmaceuticals
Conditions Diabetic Macular Edema (DME)
Enrollment 3 participants
Start Date 2025-10-02
Primary Completion 2026-04-17 (estimated)
Study Completion 2026-04-17 (estimated)
Updated on ClinicalTrials.gov 2026-05-11